SEARCH:   Advanced

Blood, 1 January 2004, Vol. 103, No. 1, pp. 333-339. Prepublished online as a Blood First Edition Paper on September 4, 2003; DOI 10.1182/blood-2003-03-0940. This Article Full Text Full Text (PDF) All Versions of this Article: 2003-03-0940v1 103/1/333    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Seftel, M. D. Articles by Hogge, D. E. Search for Related Content PubMed PubMed Citation Articles by Seftel, M. D. Articles by Hogge, D. E. Related Collections Hemostasis, Thrombosis, and Vascular Biology Neoplasia Transfusion Medicine Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSFUSION MEDICINE Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness Matthew D. Seftel, Gershon H. Growe, Tanya Petraszko, W. Barrett Benny, Alan Le, Chao-Yong Lee, John J. Spinelli, Heather J. Sutherland, Peter Tsang, and Donna E. Hogge From the Leukemia/Bone Marrow Transplantation (BMT) Program of British Columbia, and the Divisions of Hematology and Hematopathology, Vancouver General Hospital, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC. Randomized controlled trials have shown a reduction in platelet alloimmunization and refractoriness in patients with acute leukemia (AL) with the use of poststorage leukoreduction of blood products. Universal prestorage leukoreduction (ULR) of red cell and platelet products has been performed in Canada since August 1999. We conducted a retrospective analysis of 13 902 platelet transfusions in 617 patients undergoing chemotherapy (CT) for AL or stem cell transplantation (SCT) before (n = 315) and after (n = 302) the introduction of ULR. Alloimmunization was significantly reduced (19% to 7%, P < .001) in the post-ULR group. Alloimmune platelet refractoriness was similarly reduced (14% to 4%, P < .001). Fewer patients in the post-ULR group received HLA-matched platelets (14% vs 5%, P < .001). Alloimmunization and alloimmune refractoriness in the 318 patients who were previously pregnant and/or transfused were also reduced after ULR (P = .023 and P = .005, respectively). In a Cox regression model, the 3 independent factors that predicted for alloimmune refractoriness were nonleukoreduced blood products (relative risk [RR], 2.2 [95% CI, 1.2-4.3]), a history of pregnancy and/or transfusion (RR, 2.3 [95% CI, 1.3-4.2]), and receipt of 13 or more platelet transfusions (RR, 6.0 [95% CI, 2.4-15.3]). In conclusion, ULR reduces alloimmunization, refractoriness, and requirements for HLA-matched platelets when applied as routine transfusion practice to patients receiving CT or SCT. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: T. R. Klumpp and D. L. Siegel Transfusion medicine ASH Self-Assessment Program, January 1, 2007; 2007(1): 408 - 443. [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020